Arbovax Completes Successful Pre-Clinical Trial of Tetravalent Dengue Vaccine
Arbovax Completes Successful Pre-Clinical Trial of Tetravalent Dengue Vaccine
Successful Pre-Clinical Tests Support Vaccine Platform, New Injection Protocol
Raleigh N.C., March 18,..
-------------------------------------------------------------------------------------------------------------
Arbovax to present at World Vaccine Congress Lyon
Arbovax,
Inc. to speak at 13 th World Vaccine Congress, Lyon France
Arbovax,
a Bio-technology Company based in Raleigh, NC is scheduled to present their one
shot vaccine platform technology at the World Vaccine Congress in Lyon 10 th
to the 12 th Octobe..
-------------------------------------------------------------------------------------------------------------
One-shot Dengue Fever Vaccine Moves Closer to Reality
In the last decade Dengue Fever
has reemerged as a major health threat, not just in the Far East, but in the
Americas. According the World Health Organization, two-fifths of the world’s
population is at risk,..
-------------------------------------------------------------------------------------------------------------
Arbovax Completes Primate Trials
Arbovax Passes Significant Milestone in the Development of a Vaccine against Dengue Fever
Novel Approach Yields Promising Results in Primate Trials
October 12,..
-------------------------------------------------------------------------------------------------------------
Arbovax, Inc. To start pre-clinical Dengue vaccine trials
Arbovax, Inc. To start pre-clinical Dengue vaccine trials
RALEIGH, N.C., 21 April 2010 — Arbovax, an early-stage company developing vaccines against insect-borne diseases,..
-------------------------------------------------------------------------------------------------------------
Piedmont Angel Network Two Announces Investment in Arbovax, an Early-Stage Vaccine Technology Development Company
Greensboro, NC – The Piedmont Angel Network Two (PAN Two), a structured, committed capital angel fund located in Greensboro, North Carolina, is pleased to announce that it led, along with contributions from management and individual investors,..
-------------------------------------------------------------------------------------------------------------
|
 |
| |
|
